EpCAM+ tumor cells in the ascites fluid were significantly reduced after catumaxomab treatment to a median of zero after the last infusion (pooled population, Fig. 4a): 95/115 patients had a tumor-cell count of zero after the last infusion. This evidence concerns the gene EPCAM and neoplasm.